[Antiplatelet therapy during coronary endoprosthesis placement]

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Coronary stent implantation is a routine procedure for de novo lesions and bail-out situations.
• Traditional antithrombotic regimens like coumadin have been ineffective in preventing subacute stent thrombosis.
• Subacute stent thrombosis remains a significant complication following coronary stent procedures.

Purpose of the Study:

• To evaluate the effectiveness of different antithrombotic strategies in preventing subacute stent thrombosis.
• To assess the impact of novel antiplatelet therapies on stent thrombosis rates.
• To explore the potential of new pharmacological agents in expanding stent implementation, particularly in acute coronary syndromes.

Main Methods:

• Review of existing antithrombotic pharmacological regimens, including coumadin and antiplatelet therapies (ticlopidine with aspirin).
• Evaluation of the efficacy of routine heparin use and adjunctive techniques like ultrasound-guided stenting or high-pressure balloon expansion.
• Investigation of novel approaches such as fibrinogen receptor antagonists (anti-GP IIb-IIIa inhibitors).

Main Results:

• Coumadin-based regimens failed to prevent subacute stent thrombosis.
• New antiplatelet therapy, specifically ticlopidine (alone or with aspirin), reduced subacute thrombosis rates to 1%.
• Routine heparin combination and techniques like ultrasound guidance or high-pressure balloon expansion did not demonstrate a benefit in thrombosis prevention.

Conclusions:

• Novel antiplatelet therapies have significantly improved outcomes by reducing subacute stent thrombosis.
• Fibrinogen receptor antagonists represent a promising pharmacological approach for future stent implementations, especially in acute coronary syndromes.
• Further research into advanced pharmacological agents is warranted to optimize stent procedure safety and efficacy.